Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Consensus Rating of “Moderate Buy” by Analysts

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) has been assigned a consensus rating of “Moderate Buy” from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $38.3333.

Several analysts have recently issued reports on PHAR shares. Oppenheimer reiterated an “outperform” rating and set a $41.00 price target (down from $42.00) on shares of Pharming Group in a research note on Friday, March 13th. Canaccord Genuity Group initiated coverage on Pharming Group in a research note on Friday, April 10th. They issued a “buy” rating and a $37.00 price objective on the stock. Zacks Research raised Pharming Group from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. HC Wainwright reiterated a “buy” rating and set a $37.00 price target on shares of Pharming Group in a report on Tuesday, March 24th. Finally, Weiss Ratings upgraded Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, April 27th.

Hedge Funds Weigh In On Pharming Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PHAR. EverSource Wealth Advisors LLC acquired a new position in Pharming Group during the second quarter valued at approximately $32,000. SmartHarvest Portfolios LLC acquired a new position in Pharming Group during the fourth quarter valued at approximately $224,000. Millennium Management LLC acquired a new position in Pharming Group during the fourth quarter valued at approximately $360,000. Finally, NewEdge Advisors LLC grew its holdings in Pharming Group by 11,310.3% during the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after purchasing an additional 28,615 shares during the last quarter. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Stock Down 3.5%

PHAR stock opened at $16.39 on Tuesday. The company has a current ratio of 2.59, a quick ratio of 2.03 and a debt-to-equity ratio of 0.33. Pharming Group has a 1 year low of $8.60 and a 1 year high of $21.34. The company has a fifty day simple moving average of $16.39 and a 200 day simple moving average of $16.55. The firm has a market cap of $1.16 billion, a PE ratio of 1,639.00 and a beta of 0.04.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, March 12th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.08). Pharming Group had a return on equity of 1.08% and a net margin of 0.71%.The business had revenue of $106.50 million for the quarter, compared to analyst estimates of $111.76 million. Sell-side analysts anticipate that Pharming Group will post 0.38 EPS for the current fiscal year.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.